SCHEMBL4890813

SCHEMBL4890813

NCCCCCC(N)CCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.59
S1PR2 O95136 1/20 0.54
S1PR4 O95977 1/20 0.54
S1PR1 P21453 1/20 0.54
S1PR3 Q99500 1/20 0.54
HTR2A P28223 2/20 0.48
CYP2A6 P11509 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
CPB2 Q96IY4 2/20 0.47
MMP2 P08253 1/20 0.46
SIGMAR1 Q99720 1/20 0.45
ANPEP P15144 2/20 0.43
ERAP1 Q9NZ08 2/20 0.43
ERAP2 Q6P179 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10436202 0.98 MAOA (0.57) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28307957 0.92 MAOA (0.57) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28163522 0.91 MAOA (0.67) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28306964 0.91 MAOA (0.55) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28307956 0.91 MAOA (0.55) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28163398 0.89 MAOA (0.64) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL11805109 0.85 S1PR2 (0.62) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL28163397 0.85 MAOA (0.63) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL3585497 0.84 HTR2A (0.56) MAOAS1PR2S1PR4S1PR1S1PR3
SCHEMBL4895850 0.84 EPHX1 (0.56) MAOAS1PR2S1PR4S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402673-B2 Diamine β2 adrenergic receptor agonists THERAVANCE, INC. (US) 2008-07-22 US disclosed
US-20080039495-A1 Diamine Beta2 Adrenergic Receptor Agonists THERAVANCE BIOPHARMA R&D IP, LLC 2008-02-14 US disclosed
EP-1751086-A2 DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS Theravance, Inc. (US) 2007-02-14 EP disclosed
WO-2005121065-A2 DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS THERAVANCE, INC. (US) 2005-12-22 WO disclosed
US-20050272769-A1 Diamine beta2 adrenergic receptor agonists THERAVANCE, INC. (US) 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272769-A1 Diamine beta2 adrenergic receptor agonists ADRB2, ADRB1, ADRA2C MAOA 294/4885S1PR2 99/4885S1PR4 230/4885
US-20080039495-A1 Diamine Beta2 Adrenergic Receptor Agonists ADRB2, ADRB1, ADRA2C MAOA 294/4885S1PR2 99/4885S1PR4 230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.